Please assess the completion status of the following clinical trial:

Trial Title: New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 12 years and above~* Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months~* Pre-bronchodilator FEV1 ≥ 45% and ≤ 85% of predicted normal~* Patients with reversible airway obstruction~* Documented daily use of inhaled corticosteroids for ≥ 3 months~Exclusion Criteria:~* History of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2~* Hospitalized during previous 6 months for asthma~* Required emergency treatment more than once during previous 6 months for an asthma-related condition~* Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment~* Respiratory infection affecting the asthma within 30 days

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Symbicort/inhaler (Type: ACTIVE_COMPARATOR): Symbicort BA MDI 2x160/4.5 μg twice daily
- Symbicort/inhaler (Type: ACTIVE_COMPARATOR): Symbicort AC pDMI 2x160/4.5 μg twice daily
- Budesonide/inhaler (Type: ACTIVE_COMPARATOR): Budesonide AC pMDI 2x160 μg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).